Physician profile
Michael Cohen
NPI 1891783551
$18,353.92
in general payments reported to CMS, 2019-2025
59 companies · $3,780 in 2025
The $3,780 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,858 · 2020: $1,876 · 2021: $1,974 · 2022: $2,408 · 2023: $3,276 · 2024: $3,181 · 2025: $3,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,137.37 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,387.04 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Novartis Pharmaceuticals Corporation | $1,362.42 | 2019-2025 | |
| Ucb, INC. | $1,183.82 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Biogen, INC. | $1,161.64 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Lilly USA, LLC | $922.30 | 2019-2025 | Emgality, Amyvid, Reyvow |
| Emd Serono, INC. | $908.37 | 2019-2025 | Mavenclad |
| Lundbeck LLC | $816.89 | 2019-2025 | Vyepti, Rexulti |
| Celgene Corporation | $785.64 | 2020-2025 | Zeposia |
| Pfizer INC. | $635.90 | 2020-2025 | |
| Genentech USA, INC. | $550.25 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Amgen INC. | $537.66 | 2019-2025 | Uplizna, Repatha, Aimovig |
| Harmony Biosciences LLC | $509.39 | 2020-2025 | Wakix |
| Abiomed | $485.79 | 2019-2021 | |
| Eisai INC. | $482.29 | 2019-2025 | |
| Allergan, INC. | $481.30 | 2019-2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.